Scarica l'app Stockscreener
514.06
7.58%
-42.16
Dopo l'orario di chiusura:
516.79
2.73
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Pfizer inks licensing deal with Madrigal for MASH candidate - MSN
Madrigal Pharmaceuticals (MDGL) Secures Global License for Ervog - GuruFocus
Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat - MarketScreener
Pfizer in pact with Madrigal for MASH drug (MDGL:NASDAQ) - Seeking Alpha
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline - Investing.com
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline By Investing.com - Investing.com India
Madrigal Pharmaceuticals Expands Pipeline with Exclusive License Agreement for Ervogastat, Enhancing Leadership in MASH Therapies - Quiver Quantitative
Drug combo planned to target liver fat in patients with MASH - Stock Titan
What Madrigal Pharmaceuticals (MDGL)'s Valuation-Driven Analyst Downgrade Means For Shareholders - Sahm
US Stocks Recap: How Madrigal Pharmaceuticals Inc YDO1 stock trades pre earningsShare Buyback & Smart Swing Trading Alerts - moha.gov.vn
Is Madrigal Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Risk Managed Investment Entry Signals - ulpravda.ru
Is Madrigal Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Rallies & Community Trade Idea Sharing Platform - ulpravda.ru
Will Madrigal Pharmaceuticals Inc. stock deliver better than expected guidance - ulpravda.ru
How Madrigal Pharmaceuticals Inc. (YDO1) stock trades pre earningsJuly 2025 Highlights & Verified Momentum Watchlists - ulpravda.ru
Why Madrigal Pharmaceuticals stock slumped on Tuesday - MSN
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - Finviz
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.4%Time to Sell? - MarketBeat
Madrigal Pharmaceuticals (MDGL) Downgraded Amid Valuation Concer - GuruFocus
Wolfe Research downgrades Madrigal Pharmaceuticals stock on valuation concerns By Investing.com - Investing.com Canada
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - Finviz
Assessing Madrigal Pharmaceuticals (MDGL) Valuation As Rezdiffra Revenue Tops US$1b Amid Intensifying MASH Competition - Sahm
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade - Seeking Alpha
Madrigal Pharmaceuticals Earnings Notes - Trefis
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
MASH Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
(MDGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Madrigal Pharmaceuticals expands workforce with new equity grants to staff - MSN
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Madrigal uses equity incentives to lure talent as MASH drug scales up - MSN
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockLarge Cap Stability Picks & Consistently Superior Profits - earlytimes.in
Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up - MyChesCo
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight - MyChesCo
Madrigal Pharmaceuticals (MDGL) Is Up 5.4% After REZDIFFRA Phase 3 Data And CFO HireHas The Bull Case Changed? - Sahm
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week HighHere's What Happened - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD - Investing.com
Voya Investment Management LLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
(MDGL) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Bullish Rezdiffra Data, FDA Designations and Analyst Upgrades - Sahm
Trend Report: How strong is Madrigal Pharmaceuticals Inc stock revenue growthQuarterly Profit Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Madrigal Pharmaceuticals Stock Soars as Analysts Raise Price Targets - StocksToTrade
Madrigal Pharmaceuticals Sees Bullish Price Target Increases Amid Market Excitement - timothysykes.com
What consensus target says about Madrigal Pharmaceuticals Inc. (YDO1) stockJuly 2025 Catalysts & Safe Capital Preservation Plans - ulpravda.ru
Madrigal Pharmaceuticals Sees Steady Surge with Revised Analyst Ratings - StocksToTrade
Madrigal Pharmaceuticals Sees Optimistic Price Target Upgrades Amid Expansion Expectations - StocksToTrade
Madrigal Pharmaceuticals’ Stock Surge: Analyzing Latest Price Target Upgrades - timothysykes.com
Madrigal Pharmaceuticals Sees Price Targets Raised Amid Rezdiffra Optimism - timothysykes.com
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):